These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10328990)

  • 21. Preliminary experience with pure antiestrogens.
    Howell A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4369s-4375s; discussion 4411s-4412s. PubMed ID: 11916227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?
    Wakeling AE
    J Steroid Biochem Mol Biol; 1993 Dec; 47(1-6):107-14. PubMed ID: 8274423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
    McDaniel RE; Maximov PY; Jordan VC
    Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pure antiestrogens as a new therapy for breast cancer.
    England GM; Jordan VC
    Oncol Res; 1997; 9(8):397-402. PubMed ID: 9436192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
    Tobias JS
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2112-9. PubMed ID: 15313457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
    Robertson JF
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonistic and agonistic effects of tamoxifen: significance in human cancer.
    Gallo MA; Kaufman D
    Semin Oncol; 1997 Feb; 24(1 Suppl 1):S1-71-S1-80. PubMed ID: 9045319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antiestrogens: mechanism of action and clinical applications].
    Barrón-González A; Arias-Martínez J; Castro-Romero I
    Salud Publica Mex; 2001; 43(6):577-84. PubMed ID: 11816234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens.
    Howell A; Dowsett M
    Breast Cancer Res; 2004; 6(6):269-74. PubMed ID: 15535858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Molecular aspects of different mechanisms of tamoxifen resistance].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
    Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
    J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing role of the oestrogen receptor in the life and death of breast cancer cells.
    Jordan VC; Osipo C; Schafer JM; Fox JE; Cheng D; Liu H
    Breast; 2003 Dec; 12(6):432-41. PubMed ID: 14659118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo models for endocrine-dependent breast carcinomas: special considerations of clinical relevance.
    Fichtner I; Becker M; Zeisig R; Sommer A
    Eur J Cancer; 2004 Apr; 40(6):845-51. PubMed ID: 15120040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of response to tamoxifen among Iraqi patients with advanced breast cancer.
    al-Alwan NA; al-Kubaisy W; al-Rawaq K
    East Mediterr Health J; 2000; 6(2-3):475-82. PubMed ID: 11556039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
    Journe F; Chaboteaux C; Dumon JC; Leclercq G; Laurent G; Body JJ
    Br J Cancer; 2004 Nov; 91(9):1703-10. PubMed ID: 15477866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.